Healthcare sector in India is one of the largest in terms of employment as well as in revenue. Around 80 % of healthcare rests with private sector. The government healthcare is basically covered in rural area with primary healthcare centre, which provides succour to basic ailments. It also has speciality hospitals in major cities and reputed healthcare in metro cities. However, it is the private sector that provides majority of secondary, tertiary and quaternary care institutions with a major concentration in metros, tier I and tier II cities.
India also provides contrast in healthcare with high malnutrition, higher infant mortality rate, under vaccinated children and on the other side, India have medical tourism with world class facilities. The Indian healthcare industry is
After a negligence for several decades, the current union government has set up a ambitious target of bringing 100 million families under Universal Healthcare. It will be largely a state funded exercise under National Health Protecion Scheme which will provide health cover for Rs. 5.0 lakh per family. The move will provide fillip for demand in healthcare of medical equipment and other services. The scheme also envisages setting up of 1.5 lakh health and wellness centre with an investment of Rs. 12000 million. Now, the national market for healthcare is estimated at USD 100 billion.
Patients who need to be monitored are always kept under intensive care unit - which has an array of monitoring instruments which aids the doctor in clinical decision making. Now, with advent of cloud and remote access, many devices are in the market which provide continuous monitoring without expensive need for ICU. Now cloud connected smart remote monitors enable live streaming of patient vitals on central tablet and the mobile app. This can provide a inexpensive way to record vitals and can aid doctors who can access data anytime anywhere.
Gujarat Food and Drug Control Administration (FDCA) has appointed 4,000 retail pharmacies to distribute anti-TB drugs to patients not covered under the government healthcare programme. These designated pharmacies will stock and sell medicines for TB patients and help get patient?s details in an effective way. Gujarat FDCA is also supporting National Rural Health Mission (NRHM) by sharing relevant details of the patients not covered under the Revised National Tuberculosis Programme (RNTCP). There are around 37,650 retail and wholesale pharmacies in the state of Gujarat.
Council of Scientific and Industrial Research (CSIR) - Institute of Genomics & Integrative Biology (CSIR-IGIB) has decided to commercialise a set of 27 genetics tests it has developed over the years. The institute has entered into an agreement with Dr Lal PathLabs, which has a large network of network of diagnostic centres across the country, for licensing the genetic tests. These tests are expected to be launched in phases over the year. It is estimated that over 70 million Indians have been affected by rare genetic diseases. The new tests cover a variety of diseases/ disorders including movement disorders, motor neuron disease, mitochondrial disorders, developmental and inborn error of metabolism, and leukodystrophies. The project is funded through the Fast-Track Translation (FTT) Resear
Kerala Government is planning to produce anti-rabies vaccine in the state. It will produce the vaccine at the Institute of Animal Health and Veterinary Biologicals (IAH&VB) at Palode near Thiruvananthapuram, under the state Animal Husbandry Department. The institute at present produces viral and bacterial vaccines against cattle and poultry diseases. It plans to produce a total of 10 million doses of both human and animal anti-rabies vaccine. Currently, the state procures vaccine from Hyderabad-based Indian Immunologicals Limited (IIL), a subsidiary of National Dairy Development Board.
Indian government has launched Bedaquiline, a new anti-TB drug for Drug Resistant TB (DR TB) as part of the Revised National Tuberculosis Control Program (RNTCP). The drug is a new anti-TB drug for treatment of MDR-TB. This new class of drug is a diarylquinoline that specifically targets Mycobacterial ATP synthase, an enzyme essential for supply of energy to Mycobacterium tuberculosis and most other mycobacteria. This drug is indicated for use in the treatment of drug-resistant TB. Bedaquiline is being introduced at six identified tertiary care centres across India. These sites have advanced facilities for laboratory testing and intensive care for patients. Bedaquiline will be given to multi-drug resistant TB patients with resistance to either all fluoroquinolone and/or all second line inj
King's College Hospital, one of the UK's largest teaching hospitals is planning set up a 1,000-bed world-class medical facility in Andhra Pradesh's new capital Amaravati in Andhra Pradesh. The UK based company is also planning to set up 11 hospitals around India with a capacity of 11000 beds. Indo UK Healthcare, a division of the group is venturing to set up its first hospital in Chandigarh in Haryana.
Aditi Healthcare, Rajkot-based company has launched an alcohol-free hand sanitizer under the name 'ZapCare'. Unlike alcohol-based sanitizers, the water-based product kills germs without having a drying effect on the skin. It is a foaming, non-alcohol instant antimicrobial hand sanitizer that does not have medicinal odour, contains aloe vera for moisturising the skin and vitamin-E that ensures that the skin does not dry out. The sanitizer does not require rinsing and will have to be rubbed on the hands and let to dry.
Indian Council of Medical Research is set to launch an indigenous and cost-effective diagnostic tool for tuberculosis (TB) by 2016. A Bengaluru-based company has made the new diagnostic tool is as good as GeneXpert test. The idea is to reduce the cost and have an indigenous diagnostic tool, where GeneXpert test is imported. The evaluation will be over in the next three months. If it is found to be good, production will be scaled up. That may take another six months or so. It maybe a year before the diagnostic tool is available. ICMR is also working on developing vaccines for major infections, malaria and HIV. The phase-one trial for malaria vaccine should start very soon as the necessary approvals have been obtained. It has applied for regulatory clearance to start the phase-three trial